Fri, 07 Oct 2022

NEW YORK, NY / ACCESSWIRE / September 22, 2022 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Enochian Biosciences Inc. ('Enochian' or the 'Company') (NASDAQ:ENOB) and certain of its officers, on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Enochian securities between September 24, 2020 and May 31, 2022, both dates inclusive (the 'Class Period'). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/enob.

Bronstein, Gewirtz and Grossman, LLC, Thursday, September 22, 2022, Press release picture

This class action seeks to recover damages against Defendants for alleged violations of the Securities Exchange Act of 1934 (the 'Exchange Act').

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Gumrukcu was not a licensed doctor and had no verifiable degrees beyond high school; (2) accordingly, the scientific and technological underpinnings of Enochian's product pipeline, purportedly invented by Gumrukcu, were dubious at best; (3) accordingly, the Defendants had significantly overstated the commercial prospects for the Company's product pipeline; (4) Enochian's senior leadership knew Gumrukcu had a criminal history that included fraud; (5) accordingly, Enochian's reliance on Gumrukcu, and its consulting and licensing agreements with G-Tech and SRI, subjected the Company to a heightened risk of reputational and financial harm, as well as threatened the integrity of the Company's scientific findings; and (6) as a result, the Company's public statements were materially false and misleading at all relevant times.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/enob or you may contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Enochian you have until September 26, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/716868/DEADLINE-ALERT-Bronstein-Gewirtz-Grossman-LLC-Reminds-Enochian-Biosciences-Inc-ENOB-Investors-of-Class-Action-and-Last-Days-to-Actively-Participate

Sign up for Denver News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!